Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02465060
Title Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

multiple myeloma

Advanced Solid Tumor

lymphoma

Therapies

Erdafitinib

Copanlisib

Trametinib

Crizotinib

Sunitinib

Sapanisertib

Nivolumab

AZD4547

Dasatinib

Pertuzumab + Trastuzumab

Dabrafenib + Trametinib

Binimetinib

Adavosertib

Osimertinib

Palbociclib

Afatinib

Capivasertib

Defactinib

GSK2636771

Vismodegib

Ado-trastuzumab emtansine

Larotrectinib

Taselisib

Age Groups: adult
Covered Countries USA